Acuta Capital Partners, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Acuta Capital Partners, LLC reported 32 stock positions worth $153.9 million. Its top holding was Ocular Therapeutix (OCUL) at 15.6% of the portfolio, followed by Praxis Precision Medicines I (PRAX, 6.4%) and Mersana Therapeutics (6.3%). Compared with Q4 2023, it opened 6 new positions, sold out of 11, added to 7 and reduced 17. The biggest buy was Ocular Therapeutix (OCUL, shares +101%) and the biggest sale an exit from Rayzebio (RYZB).
- Most Recent 13F
- Q2 2026
- Location
- REDWOOD CITY, CA
- CIK
- 0001582844
- Portfolio Value
- $153.9M (Q1 2024)
- SEC Filing
- 0001104659-24-061603 ↗ filed May 15, 2024
Holdings Value
Holdings 32 stocks · $153.9M
| OCUL Ocular Therapeutix Inc. | 15.58% | 2,635,287 | $24.0M | Add +101.2% |
| PRAX Praxis Precision Medicines I | 6.43% | 162,302 | $9.9M | Reduce -45.8% |
| MERSANA THERAPEUTICS INC | 6.30% | 2,164,628 | $9.7M | Reduce -8.6% |
| TSHA Taysha Gene Therapies Inc. | 6.22% | 3,333,333 | $9.6M | Reduce -7.1% |
| RCKT Rocket Pharmaceuticals Inc. | 5.72% | 326,787 | $8.8M | Reduce -10.7% |
| SRPT Sarepta Therapeutics Inc. | 5.40% | 64,162 | $8.3M | Reduce -9.1% |
| PCVX Vaxcyte Inc. | 4.65% | 104,830 | $7.2M | Reduce -10.7% |
| ELVN Enliven Therapeutics Inc. | 4.53% | 396,099 | $7.0M | Add +219.8% |
| TRML Tourmaline Bio Inc. | 3.88% | 261,108 | $6.0M | Add +12.6% |
| APLT Applied Therapeutics Inc. | 3.50% | 792,000 | $5.4M | Add +50.8% |
| DYN Dyne Therapeutics Inc. | 3.40% | 184,500 | $5.2M | Add +24.8% |
| IRON Disc Medicine Inc. | 3.11% | 76,800 | $4.8M | Reduce -33.5% |
| RVMD Revolution Medicines Inc. | 3.01% | 143,777 | $4.6M | Reduce -10.1% |
| CLDX Celldex Therapeutics Inc. | 2.97% | 109,000 | $4.6M | Add +57.1% |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 2.81% | 1,849,402 | $4.3M | No change |
| HLVX Hillevax Inc. | 2.71% | 250,609 | $4.2M | Reduce -22.8% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.38% | 78,403 | $3.7M | Reduce -10.4% |
| VRDN Viridian Therapeutics Inc. | 2.27% | 199,433 | $3.5M | Reduce -29.1% |
| TERN Terns Pharmaceuticals Inc. | 1.98% | 465,079 | $3.1M | Reduce -16.2% |
| IMVT Immunovant Inc. | 1.94% | 92,346 | $3.0M | Reduce -22.7% |
| VSTM Verastem Inc. | 1.59% | 207,095 | $2.4M | Reduce -10.8% |
| ACLX Arcellx Inc. | 1.56% | 34,500 | $2.4M | Reduce -55.2% |
| KURA Kura Oncology Inc. | 1.25% | 90,000 | $1.9M | Reduce -87.2% |
| INSM Insmed Inc. | 1.09% | 61,718 | $1.7M | Add +109.2% |
| AGIO Agios Pharmaceuticals Inc. | 1.05% | 55,262 | $1.6M | New |
| ORIC Oric Pharmaceuticals Inc. | 0.93% | 103,992 | $1.4M | New |
| MREO Mereo Biopharma Group PL-ADR | 0.85% | 397,884 | $1.3M | New |
| LYRA Lyra Therapeutics Inc. | 0.70% | 173,320 | $1.1M | New |
| CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC | 0.61% | 354,166 | $942K | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 0.61% | 20,000 | $934K | New |
| ITCI Intra-Cellular Therapies Inc. | 0.60% | 13,300 | $920K | New |
| CLRB Cellectar Biosciences Inc. | 0.37% | 143,500 | $571K | Reduce -70.0% |
Other holdings (1): bonds, preferreds, convertibles and warrants · $27K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 90,832 | $27K | No change |
Total filed on the 13F, all lines: $153.9M.
Portfolio Sells Q4 2023 → Q1 2024
| RYZB Rayzebio Inc. | Sold out | 0.00% | −13.23 |
| CBAY Cymabay Therapeutics Inc. | Sold out | 0.00% | −6.54 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −5.53 |
| KURA Kura Oncology Inc. | Reduce -87.2% | 1.25% | −4.43 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −2.56 |
| ANTX AN2 Therapeutics Inc. | Sold out | 0.00% | −1.52 |
| VRDN Viridian Therapeutics Inc. | Reduce -29.1% | 2.27% | −1.18 |
| IMVT Immunovant Inc. | Reduce -22.7% | 1.94% | −0.90 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −0.85 |
| ACLX Arcellx Inc. | Reduce -55.2% | 1.56% | −0.85 |
| IRON Disc Medicine Inc. | Reduce -33.5% | 3.11% | −0.65 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −0.51 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -10.7% | 5.72% | −0.46 |
| CLRB Cellectar Biosciences Inc. | Reduce -70.0% | 0.37% | −0.37 |
| HLVX Hillevax Inc. | Reduce -22.8% | 2.71% | −0.23 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −0.21 |
| SWTX Springworks Therapeutics Inc. | Sold out | 0.00% | −0.21 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −0.17 |
| TYRA Tyra Biosciences Inc. | Sold out | 0.00% | −0.07 |
| TERN Terns Pharmaceuticals Inc. | Reduce -16.2% | 1.98% | −0.05 |
| RVMD Revolution Medicines Inc. | Reduce -10.1% | 3.01% | +0.43 |
| PCVX Vaxcyte Inc. | Reduce -10.7% | 4.65% | +0.50 |
| VSTM Verastem Inc. | Reduce -10.8% | 1.59% | +0.52 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -10.4% | 2.38% | +0.63 |
| SRPT Sarepta Therapeutics Inc. | Reduce -9.1% | 5.40% | +1.56 |
| TSHA Taysha Gene Therapies Inc. | Reduce -7.1% | 6.22% | +2.64 |
| PRAX Praxis Precision Medicines I | Reduce -45.8% | 6.43% | +2.68 |
| MERSANA THERAPEUTICS INC | Reduce -8.6% | 6.30% | +3.21 |
Portfolio Buys Q4 2023 → Q1 2024
| OCUL Ocular Therapeutix Inc. | Add +101.2% | 15.58% | +12.29 |
| ELVN Enliven Therapeutics Inc. | Add +219.8% | 4.53% | +3.56 |
| APLT Applied Therapeutics Inc. | Add +50.8% | 3.50% | +2.51 |
| DYN Dyne Therapeutics Inc. | Add +24.8% | 3.40% | +2.30 |
| CLDX Celldex Therapeutics Inc. | Add +57.1% | 2.97% | +1.42 |
| AGIO Agios Pharmaceuticals Inc. | New | 1.05% | +1.05 |
| ORIC Oric Pharmaceuticals Inc. | New | 0.93% | +0.93 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.85% | +0.85 |
| LYRA Lyra Therapeutics Inc. | New | 0.70% | +0.70 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 0.61% | +0.61 |
| ITCI Intra-Cellular Therapies Inc. | New | 0.60% | +0.60 |
| INSM Insmed Inc. | Add +109.2% | 1.09% | +0.57 |
| TRML Tourmaline Bio Inc. | Add +12.6% | 3.88% | +0.47 |
Options Activity Q4 2023 → Q1 2024
| AVXL Anavex Life Sciences Corp. | put | Sold out | 1,000 | $23Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $143.5M | PRAX, WHWK, TNGX, STRO, AVBP |
| Q1 2026 | 26 | $140.6M | PRAX, TERN, WHWK, TNGX, DRUG |
| Q4 2025 | 29 | $147.3M | TERN, PRAX, CDTX, OCUL, WHWK |
| Q3 2025 | 27 | $96.8M | OCUL, CDTX, TRML, WHWK, INSM |
| Q2 2025 | 27 | $71.6M | OCUL, CDTX, WHWK, SLNO, TRML |
| Q1 2025 | 33 | $86.2M | OCUL, INSM, TRML, WHWK, ELVN |
| Q4 2024 | 38 | $99.4M | OCUL, INSM, TRML, CRNX, ELVN |
| Q3 2024 | 40 | $123.5M | PCVX, OCUL, TRML, INSM, ELVN |
| Q2 2024 | 31 | $118.6M | OCUL, ELVN, PCVX, DYN, PRAX |
| Q1 2024 | 32 | $153.9M | OCUL, PRAX, MERSANA THERAPEUTICS INC, TSHA, RCKT |